WO2016114928A1 - Mitral bileaflet valve - Google Patents

Mitral bileaflet valve Download PDF

Info

Publication number
WO2016114928A1
WO2016114928A1 PCT/US2015/068020 US2015068020W WO2016114928A1 WO 2016114928 A1 WO2016114928 A1 WO 2016114928A1 US 2015068020 W US2015068020 W US 2015068020W WO 2016114928 A1 WO2016114928 A1 WO 2016114928A1
Authority
WO
WIPO (PCT)
Prior art keywords
leaflet
assembly
section
body portion
atrium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/068020
Other languages
French (fr)
Inventor
Min Frank ZENG
Pham LO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Horizon Scientific Corp
Original Assignee
Horizon Scientific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Scientific Corp filed Critical Horizon Scientific Corp
Priority to EP15878296.1A priority Critical patent/EP3244834B1/en
Priority to CN201580073286.9A priority patent/CN107205816B/en
Publication of WO2016114928A1 publication Critical patent/WO2016114928A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2418—Scaffolds therefor, e.g. support stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2427—Devices for manipulating or deploying heart valves during implantation
    • A61F2/2436—Deployment by retracting a sheath
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2220/0075—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0004—Rounded shapes, e.g. with rounded corners
    • A61F2230/0006—Rounded shapes, e.g. with rounded corners circular
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0004—Rounded shapes, e.g. with rounded corners
    • A61F2230/0008—Rounded shapes, e.g. with rounded corners elliptical or oval
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0028—Shapes in the form of latin or greek characters
    • A61F2230/0034—D-shaped

Definitions

  • the present invention is directed to methods, systems, and apparatus for safely replacing or repairing native heart valves with prosthetic heart valves.
  • Prosthetic heart valves have been used for many years to treat cardiac valvular disorders.
  • the native heart valves (such as the aortic, pulmonary, and mitral valves) serve critical functions in assuring the forward flow of an adequate supply of blood through the cardiovascular system.
  • These heart valves can be rendered less effective by congenital, inflammatory, or infectious conditions. Such conditions can eventually lead to serious cardiovascular compromise or death.
  • the definitive treatment for such disorders was the surgical repair or replacement of the valve during open heart surgery, but such surgeries are dangerous and prone to complication.
  • a transvascular technique for introducing and implanting a prosthetic heart valve using a flexible catheter in a manner that is less invasive than open heart surgery.
  • a prosthetic valve is mounted in a crimped state on the end portion of a flexible catheter and advanced through a blood vessel of the patient until the valve reaches the implantation site.
  • the valve at the catheter tip is then expanded to its functional size at the site of the defective native valve, such as by inflating a balloon on which the valve is mounted.
  • the valve can have a resilient, self-expanding stent or frame that expands the valve to its functional size when it is advanced from a delivery sheath at the distal end of the catheter.
  • the mitral valve annulus does not provide a good landmark for positioning a replacement mitral valve.
  • the height and width of the aortic annulus are generally increased in the presence of degenerative disease associated with calcium
  • a mitral valve annulus is therefore generally thinner than the annulus of a diseased aortic valve.
  • the thinner mitral valve annulus makes it relatively more difficult to properly seat a replacement mitral valve in the native mitral valve annulus.
  • the general anatomy of the mitral valve annulus also makes it more difficult to properly anchor a replacement mitral valve in place.
  • the mitral valve annulus provides for a smoother transition from the left atrium to the left ventricle than the transition that the aortic valve annulus provides from the aorta to the left ventricle.
  • the aortic annulus is anatomically more pronounced, providing a larger "bump" to which a replacement aortic valve can more easily be secured in place.
  • the larger mitral valve annulus makes it difficult to securely implant current percutaneously delivered valves in the native mitral position.
  • a replacement mitral valve that has a valve support structure or anchoring device that can be positioned near or within the native mitral valve.
  • the present invention provides a heart valve assembly that has a leaflet support structure and a leaflet assembly.
  • the leaflet support structure has a wire frame having an anterior atrium annulus section and a posterior atrium annulus section, with each opposite end of the atrium annulus sections transitioning to a commissure section that curves radially inwardly along the same plane as the atrium annulus sections.
  • Each commissure section transitions via a first bend to a leg which extends vertically at opposite central points of the wire frame.
  • Each leg extends vertically and slightly radially outwardly at an angle, and each leg transitions via a second bend which extends radially outwardly and transitions into a tail that extends vertically upwardly, with a gap defined between each corresponding tail and leg.
  • the leaflet assembly has first and second separate leaflets, each of which is comprised of a skirt section and a sinus leaflet section.
  • Each skirt section has a flange portion and a body portion that has a smaller diameter than the flange portion, with the body portion having opposing side edges, and a curved opening defined by a first stitching edge at about the central portion of the body portion.
  • Each sinus leaflet section has an outflow edge, and a curved second stitching edge, with the sinus leaflet section stitched to the skirt section along the first and second stitching edges.
  • the opposing side edges of the body portion of the first leaflet are stitched to the corresponding side edges of the body portion of the second leaflet.
  • FIG. 1 is a perspective view of a mitral valve device according to one embodiment of the present invention.
  • FIG. 1 A is a schematic side view of the device of FIG. 1 shown with
  • FIG. 1 B is a schematic top view of the device of FIG. 1A shown with
  • FIG. 1 C is a top view of the device of FIG. 1 shown with the valve in a fully opened position with pressure on the leaflets.
  • FIG. 1 D is a top view of the device of FIG. 1 shown with the valve in a fully closed position with pressure on the leaflets.
  • FIG. 1 E is a side view of the device of FIG. 1 shown with the valve in a fully closed position with pressure on the leaflets.
  • FIG. 2A is a perspective view of the wire frame of the mitral valve device of FIG. 1 .
  • FIG. 2B is a top view of the wire frame of FIG. 2A.
  • FIG. 2C is a side view of the wire frame of FIG. 2A.
  • FIG. 3A is a perspective conceptual view of the leaflet assembly of the mitral valve design of the device of FIG. 1.
  • FIG. 3B is a top conceptual view of the leaflet assembly design of FIG. 3A.
  • FIG. 3C is a side conceptual view of the leaflet assembly design of FIG. 3A.
  • FIG. 3D is a conceptual view of the leaflet assembly design of FIG. 3A.
  • FIG. 4A is a perspective view of one embodiment of the leaflet assembly with the tissue of the mitral valve device of FIG. 1 that is based on the conceptual model shown in FIGS. 3A-3D.
  • FIG. 4B is an exploded side view of one of the leaflets of the leaflet assembly of FIG. 4A.
  • FIG. 4C is a side view of the leaflet assembly of FIG. 4A.
  • FIG. 4D is an inside view of one of the leaflets of the leaflet assembly of FIG.
  • FIG. 4E is an outside view of one of the leaflets of the leaflet assembly of FIG. 4A.
  • FIG. 5A is a top view illustrating the closing of a conventional bileaflet valve assembly using the wire frame of FIG. 2A.
  • FIG. 5B is a perspective view illustrating the closing of a conventional bileaflet valve assembly.
  • FIG. 6A is a side view of a patient ' s heart showing the deployment of the device of FIG. 1 at the mitral annulus position.
  • FIG. 6B is a front view of a patient's heart showing the deployment of the device of FIG. 1 at the mitral annulus position, with the valve in a closed position.
  • FIG. 6C is a front view of a patient ' s heart showing the deployment of the device of FIG. 1 at the mitral annulus position, with the valve in an opened position.
  • FIG. 6D is a top schematic view of a natural human mitral valve.
  • FIG. 7 illustrates a delivery system that can be used to deploy the device of
  • FIG. 1 is a diagrammatic representation of FIG. 1 .
  • FIGS. 7A-7D illustrate how the device of FIG. 1 can be deployed at the mitral annulus of a patient ' s heart using a Transapical delivery system.
  • FIGS. 8 illustrates how the device of FIG. 1 can be deployed at the mitral annulus of a patient ' s heart using a (transfemoral or transseptal) percutaneous delivery system.
  • the present invention provides a mitral valve device 100 that is shown in fully assembled form in FIG. 1 .
  • the device 00 has a wire frame 102 (see FIGS. 2A-2C) that is adapted to carry an integrated leaflet assembly 104 (see FIGS. 3A-4D).
  • the wire frame 102 provides a simple leaflet valve support structure that can be effectively secured at the native mitral valve annulus.
  • the leaflet assembly 104 provides a novel leaflet configuration which provides fast opening and closing of the valve leaflets.
  • the overall construction of the device 100 is simple, and effective in promoting proper mitral valve function.
  • the wire frame 102 comprises an anterior atrium annulus section 7 and a posterior atrium annulus section 8, each of which extends horizontally and is shaped like half an oval.
  • a U-shaped extension 19 and 20 is provided at about the central portion of each section 7 and 8, respectively, and extends radially outwardly. These extensions 19 and 20 function to seat the device 100 on the native annulus. and for use in being held by the hooks 191 and 201 of the delivery system (see FIG. 8) during percutaneous delivery.
  • Each opposite end of the atrium annulus sections 7 and 8 transitions to a commissure section 9 and 10 that curves radially inwardly along the same plane as the atrium annulus sections 7 and 8.
  • Each leg 17 and 18 extends vertically and slightly radially outwardly at an angle (see FIG. 2C), and transitions via bends 13 and 14, respectively, which extend radially outwardly and transition into tails 131 and 141 , respectively, that extend vertically upwardly before terminating at rounded ends 16 and 15, respectively, which curve radially outwardly.
  • Gaps G1 and G2 are defined between the tail 131 and the leg 17. and the tail 141 and 18, respectively.
  • the wire frame 102 can define an oval shape (when viewed from the top), a circular shape, or a D shape.
  • FIGS. 1A and 1 B illustrate some exemplary dimensions for the device 100 as follows:
  • exemplary dimensions can be used for a device 100 that is adapted for use at the native mitral valve location for a generic adult and these dimensions will vary for devices 100 that are used for other applications, such as for a triscupid valve. These exemplary dimensions illustrate the proportions of the various elements to each other.
  • the wire frame 102 can be made of one continuous wire, and can be made from a thin wall biocompatible metallic element (such as stainless steel. Co-Cr based alloy, NitinotTM, Ta, and Ti etc.).
  • the wire can be made from a NitinolTM wire that is well-known in the art, and have a diameter of 0.2" to 0.4 " .
  • the present invention provides a novel leaflet assembly 104 that provides a better coaptation between the leaflets.
  • the leaflet assembly 104 provides two separate leaflets, each of which is comprised of an upper skirt section 1 a or 1 b, and a lower sinus leaflet section 2a or 2b.
  • sectionsl a and 2a make up one leaflet
  • sections 1 b and 2b make up the other leaflet.
  • the skirt sections 1 a and 1 b are identical, and each has a larger-diameter semi-oval flange portion 6a or 6b, and a smaller-diameter body portion 4a or 4b.
  • Each body portion 4a or 4b has opposing side edges 26a that function as commissure folding lines along which the side edges 26a may be stitched to assemble the two separate leaflets into a single leaflet assembly 104.
  • Each body portion 4a or 4b also has a central U-shaped opening defined by stitching edge 29, which is adapted to receive the curved edge of the corresponding sinus leaflet section 2a or 2b.
  • Each skirt section 1 a, 1 b creates an oval-shaped site on the top of the natural annulus.
  • Each sinus leaflet section 2a or 2b has a generally semi-circular shape, including an outflow edge 3a or 3b. and a curved edge defined by stitching edge 31 .
  • Each sinus leaflet section 2a or 2b is stitched along its stitching edge 31 to the stitching edge 29 of the corresponding body portion 4a or 4b.
  • FIGS. 6D is a top view of a natural mitral valve with six natural components labeled by A1 , A2, A3 and P 1 , P2, P3.
  • FIG. 4A the leaflet assembly 104 has the same six components where 4a, 2a and 4a correspond to A1 . A2 and A3, respectively, and 4b, 2b. 4b correspond to P 1 , P2 and P3, respectively. For this reason, the leaflet assembly 104 is able to function in a manner which comes closest to replicating the natural function of the native mitral valve.
  • FIG. 5A illustrates the wire frame 102 used with a conventional bi-leaflet valve assembly where the two leaflets must necessarily be long enough so as to allow for proper coaptation at the outflow end.
  • the sinus leaflet sections 2a, 2b can function to provide better leaflet coaptation along its outflow edges 3a. 3b while maintaining a shorter or lower profile. This in turn allows the skirt sections 1 a. 1 b to have a shorter profile.
  • a shorter profile can be important because, if the valve body is too long, it could potentially interfere with the blood flow in the aortic direction.
  • FIGS. 3A-4D compare the dimensions in FIGS. 1 B using the novel leaflet design of the present invention with the dimensions in FIG. 5A for a conventional bi-leaflet valve assembly.
  • the valve design provides a " belly sinus '' for a large opening.
  • the opening provided by a conventional bi-leaflet valve in FIG. 5A would be L0, which is 28 mm.
  • the novel leaflet design of the present invention allows the valve to open and close faster because a valve with a shorter profile and having the sinus 2a. 2b will allow for the valve to open and close completely.
  • the leaflet coaptation length will be short when the valve closes, and with the control provided by the body portions 4a, 4b when the valve is closed , this would allow the valve to open more quickly.
  • the leaflet coaptation length will be longer for the valve when it is fully closed , which takes too much time and requires greater pressure for the valve to open. Given the fact that a natural mitral valve usually opens at a pressure of 1 5 mm Hg and closes at a pressure of 140 mm Hg. these features of the novel leaflet design of the present invention allows for faster opening and closing of the valve.
  • the side edges 26a illustrate stitch lines along which the body portions 4a, 4b may be stitched to the legs 17 and 18 of the wire frame 102.
  • the edges 27a and 27b are attached to the annulus sections 7 and 8 of the wire frame 102.
  • the skirt sections 1 a and 1 b sit on the commissures of the native leaflets along the lines 5.
  • the leaflet sections 1 a, 1 b. 2a and 2b can all be made from treated animal tissue such as pericardium , or from biocompatible polymer material (such as PTFE. Dacron, bovine, porcine, etc.).
  • the leaflet sections 1 a, 1 b, 2a, 2b can also be provided with a drug or bioagent coating to improve performance, prevent thrombus formation, and promote endotheliolization, and can also be treated (or be provided) with a surface layer/coating to prevent calcification.
  • FIGS. 6A-6C illustrate the device 100 when it has been deployed at the mitral annulus position in a patient s heart.
  • the commissure sections 9 and 10 are seated on the native annulus 22, and each native leaflet 25 is positioned between a gap G 1 or G2 which is defined between the tail 1 31 and the leg 17, and the tail 141 and 18. respectively.
  • the bends 1 3 and 14 of the wire frame 102 are inserted between the chordae and the native leaflets 25 to balance the device 100. This manner of securement allows the device 100 to be securely positioned at the location of the native annulus 22.
  • the rounded ends 1 5 and 16 are positioned under the postero-median commissure (PMC) and artero-lateral commissure (ALC), and the commissure sections 10 and 9 are positioned on the PMC and ALC at the locations 62 and 61 , respectively, as shown in FIG . 6D.
  • PMC postero-median commissure
  • ALC artero-lateral commissure
  • This positioning of the device 1 00 creates a strong anchoring clip effect which prevents the device 100 from moving up and down.
  • FIG. 6B shows the leaflet assembly 104 in a closed position
  • FIG. 6C shows the leaflet assembly 104 in an opened position
  • LA is the left atrium
  • LV is the left ventricle
  • 25a is the native anterior leaflet
  • 25b is the native posterior leaflet
  • FIG. 1 C shows the valve opened
  • FIGS. 1 D and 1 E show the valve closed .
  • the device 100 of the present invention can be compacted into a low profile and loaded onto a delivery system, and then delivered to the target location by a non-invasive medical procedure, such as through the use of a delivery catheter through transapical, or transfemoral, or transseptal procedures.
  • the mitral valve replacement device can be released from the delivery system once it reaches the target implant site, and can expand to its normal (expanded) profile either by inflation of a balloon (for a balloon expandable supporting structure) or by elastic energy stored in the device (for a device with a self-expandable supporting structure).
  • FIGS. 7 and 7A-7E illustrate how the device 00 can be deployed at the mitral annulus of a patient ' s heart using a transapical delivery system.
  • the delivery system has a catheter which has an outer sheath 30 with a distal tip 37.
  • a center tube 38 extends through the outer sheath 30 and is connected to the distal tip 37, and a marker band 31 1 (see FIG. 7 A) is positioned at the distal end of the outer sheath 30.
  • 32 indicates the left and right of the marker band 31 1 .
  • Two cables 35 and 36 extend through respective tubes 33 and 34, respectively, that run through the interior of the sheath 30.
  • FIG. 7 A illustrates the device 100 in a collapsed configuration being delivered to the mitral annulus inside the sheath 30.
  • the sheath 30 is withdrawn (i.e. , moved downwardly) to expose the device so that the self-expanding wire frame 102 will deploy the anterior atrium annulus section 7 and the posterior atrium annulus section 8 in the atrium.
  • FIG. 7C the sheath 30 is further withdrawn to release the two cables 35 and 36, and the cables 35 and 36 are detached so that the tails 1 31 and 141 of the wire frame 1 02 can be inserted in the chordae under the native commissure leaflet.
  • the device 00 is deployed at the native annulus. and in FIG. 7d, the delivery system can be withdrawn .
  • the annulus sections 7 and 8 "seat" at the mitral annulus area to create a "seal” to prevent leakage (blood flow back from the left ventricle to the left atrium) from the area surrounding the device 100, This is best illustrated in FIGS, 6A-6C.
  • the opening and closing motion of the valve design of the present invention is very similar to the opening and closing motion of a natural mitral valve.

Landscapes

  • Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Prostheses (AREA)

Abstract

A heart valve assembly has a leaflet support structure and a leaflet assembly. The leaflet support structure has a wire frame that supports the leaflet assembly. The leaflet assembly has first and second separate leaflets, each of which is comprised of a skirt section and a sinus leaflet section. Each skirt section has a flange portion and a body portion that has a smaller diameter than the flange portion, with the body portion having opposing side edges, and a curved opening defined by a first stitching edge at about the central portion of the body portion. Each sinus leaflet section has an outflow edge, and a curved second stitching edge, with the sinus leaflet section stitched to the skirt section along the first and second stitching edges. The opposing side edges of the body portion of the first leaflet are stitched to the corresponding side edges of the body portion of the second leaflet.

Description

MITRAL BILEAFLET VALVE
Inventor: Mm Frank Zeng and Pham Lo
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is directed to methods, systems, and apparatus for safely replacing or repairing native heart valves with prosthetic heart valves.
2. Description of the Prior Art
Prosthetic heart valves have been used for many years to treat cardiac valvular disorders. The native heart valves (such as the aortic, pulmonary, and mitral valves) serve critical functions in assuring the forward flow of an adequate supply of blood through the cardiovascular system. These heart valves can be rendered less effective by congenital, inflammatory, or infectious conditions. Such conditions can eventually lead to serious cardiovascular compromise or death. For many years the definitive treatment for such disorders was the surgical repair or replacement of the valve during open heart surgery, but such surgeries are dangerous and prone to complication.
More recently a transvascular technique has been developed for introducing and implanting a prosthetic heart valve using a flexible catheter in a manner that is less invasive than open heart surgery. In this technique, a prosthetic valve is mounted in a crimped state on the end portion of a flexible catheter and advanced through a blood vessel of the patient until the valve reaches the implantation site. The valve at the catheter tip is then expanded to its functional size at the site of the defective native valve, such as by inflating a balloon on which the valve is mounted. Alternatively, the valve can have a resilient, self-expanding stent or frame that expands the valve to its functional size when it is advanced from a delivery sheath at the distal end of the catheter.
Unlike the aortic valve, however, the mitral valve annulus does not provide a good landmark for positioning a replacement mitral valve. In patients needing a replacement aortic valve, the height and width of the aortic annulus are generally increased in the presence of degenerative disease associated with calcium
formation. These changes in tissue make it easier to properly secure a replacement aortic valve in place due to the reduced cross-sectional area of the aortic annuius. The degenerative changes typically found in aortic valves are not, however, present in mitral valves experiencing regurgitation, and a mitral valve annulus is therefore generally thinner than the annulus of a diseased aortic valve. The thinner mitral valve annulus makes it relatively more difficult to properly seat a replacement mitral valve in the native mitral valve annulus. The general anatomy of the mitral valve annulus also makes it more difficult to properly anchor a replacement mitral valve in place. The mitral valve annulus provides for a smoother transition from the left atrium to the left ventricle than the transition that the aortic valve annulus provides from the aorta to the left ventricle. The aortic annulus is anatomically more pronounced, providing a larger "bump" to which a replacement aortic valve can more easily be secured in place.
Thus, the larger mitral valve annulus makes it difficult to securely implant current percutaneously delivered valves in the native mitral position. Some attempts have been made to deliver and implant a one-piece replacement mitral valve, but it is difficult to provide a device that can be collapsed down to have a sufficiently small delivery profile and still be able to be expanded and secured in place within the mitral valve via a vascular access site.
As a result, there remains a need for a replacement mitral valve that has a valve support structure or anchoring device that can be positioned near or within the native mitral valve.
SUMMARY OF THE DISCLOSURE
To accomplish the objectives set forth above, the present invention provides a heart valve assembly that has a leaflet support structure and a leaflet assembly.
The leaflet support structure has a wire frame having an anterior atrium annulus section and a posterior atrium annulus section, with each opposite end of the atrium annulus sections transitioning to a commissure section that curves radially inwardly along the same plane as the atrium annulus sections. Each commissure section transitions via a first bend to a leg which extends vertically at opposite central points of the wire frame. Each leg extends vertically and slightly radially outwardly at an angle, and each leg transitions via a second bend which extends radially outwardly and transitions into a tail that extends vertically upwardly, with a gap defined between each corresponding tail and leg.
The leaflet assembly has first and second separate leaflets, each of which is comprised of a skirt section and a sinus leaflet section. Each skirt section has a flange portion and a body portion that has a smaller diameter than the flange portion, with the body portion having opposing side edges, and a curved opening defined by a first stitching edge at about the central portion of the body portion. Each sinus leaflet section has an outflow edge, and a curved second stitching edge, with the sinus leaflet section stitched to the skirt section along the first and second stitching edges. The opposing side edges of the body portion of the first leaflet are stitched to the corresponding side edges of the body portion of the second leaflet.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a perspective view of a mitral valve device according to one embodiment of the present invention.
FIG. 1 A is a schematic side view of the device of FIG. 1 shown with
dimensions according to one non-limiting embodiment thereof, shown with the valve in a naturally open position without any pressure on the leaflets.
FIG. 1 B is a schematic top view of the device of FIG. 1A shown with
dimensions according to one non-limiting embodiment thereof, shown with the valve in a naturally open position without any pressure on the leaflets.
FIG. 1 C is a top view of the device of FIG. 1 shown with the valve in a fully opened position with pressure on the leaflets.
FIG. 1 D is a top view of the device of FIG. 1 shown with the valve in a fully closed position with pressure on the leaflets.
FIG. 1 E is a side view of the device of FIG. 1 shown with the valve in a fully closed position with pressure on the leaflets.
FIG. 2A is a perspective view of the wire frame of the mitral valve device of FIG. 1 .
FIG. 2B is a top view of the wire frame of FIG. 2A.
FIG. 2C is a side view of the wire frame of FIG. 2A.
FIG. 3A is a perspective conceptual view of the leaflet assembly of the mitral valve design of the device of FIG. 1. FIG. 3B is a top conceptual view of the leaflet assembly design of FIG. 3A.
FIG. 3C is a side conceptual view of the leaflet assembly design of FIG. 3A.
FIG. 3D is a conceptual view of the leaflet assembly design of FIG. 3A.
FIG. 4A is a perspective view of one embodiment of the leaflet assembly with the tissue of the mitral valve device of FIG. 1 that is based on the conceptual model shown in FIGS. 3A-3D.
FIG. 4B is an exploded side view of one of the leaflets of the leaflet assembly of FIG. 4A.
FIG. 4C is a side view of the leaflet assembly of FIG. 4A.
FIG. 4D is an inside view of one of the leaflets of the leaflet assembly of FIG.
4A.
FIG. 4E is an outside view of one of the leaflets of the leaflet assembly of FIG. 4A.
FIG. 5A is a top view illustrating the closing of a conventional bileaflet valve assembly using the wire frame of FIG. 2A.
FIG. 5B is a perspective view illustrating the closing of a conventional bileaflet valve assembly.
FIG. 6A is a side view of a patient's heart showing the deployment of the device of FIG. 1 at the mitral annulus position.
FIG. 6B is a front view of a patient's heart showing the deployment of the device of FIG. 1 at the mitral annulus position, with the valve in a closed position.
FIG. 6C is a front view of a patient's heart showing the deployment of the device of FIG. 1 at the mitral annulus position, with the valve in an opened position.
FIG. 6D is a top schematic view of a natural human mitral valve.
FIG. 7 illustrates a delivery system that can be used to deploy the device of
FIG. 1 .
FIGS. 7A-7D illustrate how the device of FIG. 1 can be deployed at the mitral annulus of a patient's heart using a Transapical delivery system.
FIGS. 8 illustrates how the device of FIG. 1 can be deployed at the mitral annulus of a patient's heart using a (transfemoral or transseptal) percutaneous delivery system. c
J
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following detailed description is of the best presently contemplated modes of carrying out the invention. This description is not to be taken in a limiting sense, but is made merely for the purpose of illustrating general principles of embodiments of the invention. The scope of the invention is best defined by the appended claims.
The present invention provides a mitral valve device 100 that is shown in fully assembled form in FIG. 1 . The device 00 has a wire frame 102 (see FIGS. 2A-2C) that is adapted to carry an integrated leaflet assembly 104 (see FIGS. 3A-4D). The wire frame 102 provides a simple leaflet valve support structure that can be effectively secured at the native mitral valve annulus. In addition, the leaflet assembly 104 provides a novel leaflet configuration which provides fast opening and closing of the valve leaflets. The overall construction of the device 100 is simple, and effective in promoting proper mitral valve function.
As shown in FIGS. 1 -2C, the wire frame 102 comprises an anterior atrium annulus section 7 and a posterior atrium annulus section 8, each of which extends horizontally and is shaped like half an oval. A U-shaped extension 19 and 20 is provided at about the central portion of each section 7 and 8, respectively, and extends radially outwardly. These extensions 19 and 20 function to seat the device 100 on the native annulus. and for use in being held by the hooks 191 and 201 of the delivery system (see FIG. 8) during percutaneous delivery. Each opposite end of the atrium annulus sections 7 and 8 transitions to a commissure section 9 and 10 that curves radially inwardly along the same plane as the atrium annulus sections 7 and 8. and then transitions via bends 1 1 and 12 to legs 17 and 18 which extend vertically at opposite central points of the wire frame 102. Each leg 17 and 18 extends vertically and slightly radially outwardly at an angle (see FIG. 2C), and transitions via bends 13 and 14, respectively, which extend radially outwardly and transition into tails 131 and 141 , respectively, that extend vertically upwardly before terminating at rounded ends 16 and 15, respectively, which curve radially outwardly. Gaps G1 and G2 are defined between the tail 131 and the leg 17. and the tail 141 and 18, respectively. The wire frame 102 can define an oval shape (when viewed from the top), a circular shape, or a D shape.
FIGS. 1A and 1 B illustrate some exemplary dimensions for the device 100 as follows:
DO: 38 mm D1 : 29 mm
D2: 34 mm
D3: 19 mm
D4: 8 mm
D5: 24 mm
H1 : 13 mm
H2: 10 mm
H3: 2 mm
L0: 28 mm
L1 : 13 mm
L2: 19 mm
L3; 6 mm
L4: 5 mm
L5: 29 mm
L6; 30 mm
These exemplary dimensions can be used for a device 100 that is adapted for use at the native mitral valve location for a generic adult and these dimensions will vary for devices 100 that are used for other applications, such as for a triscupid valve. These exemplary dimensions illustrate the proportions of the various elements to each other.
The wire frame 102 can be made of one continuous wire, and can be made from a thin wall biocompatible metallic element (such as stainless steel. Co-Cr based alloy, Nitinot™, Ta, and Ti etc.). As an example, the wire can be made from a Nitinol™ wire that is well-known in the art, and have a diameter of 0.2" to 0.4".
Referring to FIGS. 3A through 4D, the present invention provides a novel leaflet assembly 104 that provides a better coaptation between the leaflets. The leaflet assembly 104 provides two separate leaflets, each of which is comprised of an upper skirt section 1 a or 1 b, and a lower sinus leaflet section 2a or 2b. In other words, sectionsl a and 2a make up one leaflet, and sections 1 b and 2b make up the other leaflet. As best shown in FIGS. 4A-4D, the skirt sections 1 a and 1 b are identical, and each has a larger-diameter semi-oval flange portion 6a or 6b, and a smaller-diameter body portion 4a or 4b. Each body portion 4a or 4b has opposing side edges 26a that function as commissure folding lines along which the side edges 26a may be stitched to assemble the two separate leaflets into a single leaflet assembly 104. Each body portion 4a or 4b also has a central U-shaped opening defined by stitching edge 29, which is adapted to receive the curved edge of the corresponding sinus leaflet section 2a or 2b. Each skirt section 1 a, 1 b creates an oval-shaped site on the top of the natural annulus.
Each sinus leaflet section 2a or 2b has a generally semi-circular shape, including an outflow edge 3a or 3b. and a curved edge defined by stitching edge 31 . Each sinus leaflet section 2a or 2b is stitched along its stitching edge 31 to the stitching edge 29 of the corresponding body portion 4a or 4b.
The construction of the leaflet assembly 104 provides six components that correspond to the natural six components found In a native mitral valve. For example, FIGS. 6D is a top view of a natural mitral valve with six natural components labeled by A1 , A2, A3 and P 1 , P2, P3. Referring now to FIG. 4A. the leaflet assembly 104 has the same six components where 4a, 2a and 4a correspond to A1 . A2 and A3, respectively, and 4b, 2b. 4b correspond to P 1 , P2 and P3, respectively. For this reason, the leaflet assembly 104 is able to function in a manner which comes closest to replicating the natural function of the native mitral valve.
In addition, with the leaflet construction shown in FIGS. 3A-4D, the leaflet assembly 104 of the present invention provides for a shorter valve assembly which facilitates improved coaptation. For example. FIG. 5A illustrates the wire frame 102 used with a conventional bi-leaflet valve assembly where the two leaflets must necessarily be long enough so as to allow for proper coaptation at the outflow end. In contrast, by sewing the body portions 4a, 4b together in a flat or folded manner as shown in the conceptual drawings of FIGS. 3A-3C, the sinus leaflet sections 2a, 2b can function to provide better leaflet coaptation along its outflow edges 3a. 3b while maintaining a shorter or lower profile. This in turn allows the skirt sections 1 a. 1 b to have a shorter profile. A shorter profile can be important because, if the valve body is too long, it could potentially interfere with the blood flow in the aortic direction.
To illustrate the benefits provided by the novel leaflet assembly shown in FIGS. 3A-4D, compare the dimensions in FIGS. 1 B using the novel leaflet design of the present invention with the dimensions in FIG. 5A for a conventional bi-leaflet valve assembly. In FIG. 1 B, the valve design provides a "belly sinus'' for a large opening. Using the dimensions in FIG. 1 B, when the valve opens, the opening has a width of 35 mm, which is obtained by adding L1 ( 1 3 mm) + 2xL4 (5mm) + 2xL3 (6 mm)=35mm . In contrast, the opening provided by a conventional bi-leaflet valve in FIG. 5A would be L0, which is 28 mm.
The novel leaflet design of the present invention allows the valve to open and close faster because a valve with a shorter profile and having the sinus 2a. 2b will allow for the valve to open and close completely. The leaflet coaptation length will be short when the valve closes, and with the control provided by the body portions 4a, 4b when the valve is closed , this would allow the valve to open more quickly. In contrast, in a conventional bileaflet design, the leaflet coaptation length will be longer for the valve when it is fully closed , which takes too much time and requires greater pressure for the valve to open. Given the fact that a natural mitral valve usually opens at a pressure of 1 5 mm Hg and closes at a pressure of 140 mm Hg. these features of the novel leaflet design of the present invention allows for faster opening and closing of the valve.
Referring also to FIGS. 1 , 2A-2C and 4A-4E. the side edges 26a illustrate stitch lines along which the body portions 4a, 4b may be stitched to the legs 17 and 18 of the wire frame 102. In addition, the edges 27a and 27b are attached to the annulus sections 7 and 8 of the wire frame 102. The skirt sections 1 a and 1 b sit on the commissures of the native leaflets along the lines 5.
The leaflet sections 1 a, 1 b. 2a and 2b can all be made from treated animal tissue such as pericardium , or from biocompatible polymer material (such as PTFE. Dacron, bovine, porcine, etc.). The leaflet sections 1 a, 1 b, 2a, 2b can also be provided with a drug or bioagent coating to improve performance, prevent thrombus formation, and promote endotheliolization, and can also be treated (or be provided) with a surface layer/coating to prevent calcification.
FIGS. 6A-6C illustrate the device 100 when it has been deployed at the mitral annulus position in a patient s heart. As shown in FIG. 6A. the commissure sections 9 and 10 are seated on the native annulus 22, and each native leaflet 25 is positioned between a gap G 1 or G2 which is defined between the tail 1 31 and the leg 17, and the tail 141 and 18. respectively. In addition, the bends 1 3 and 14 of the wire frame 102 are inserted between the chordae and the native leaflets 25 to balance the device 100. This manner of securement allows the device 100 to be securely positioned at the location of the native annulus 22. In particular, the rounded ends 1 5 and 16 are positioned under the postero-median commissure (PMC) and artero-lateral commissure (ALC), and the commissure sections 10 and 9 are positioned on the PMC and ALC at the locations 62 and 61 , respectively, as shown in FIG . 6D. This positioning of the device 1 00 creates a strong anchoring clip effect which prevents the device 100 from moving up and down.
FIG. 6B shows the leaflet assembly 104 in a closed position, and FIG. 6C shows the leaflet assembly 104 in an opened position, where LA is the left atrium , and LV is the left ventricle. 25a is the native anterior leaflet, and 25b is the native posterior leaflet. FIG. 1 C shows the valve opened, while FIGS. 1 D and 1 E show the valve closed .
The device 100 of the present invention can be compacted into a low profile and loaded onto a delivery system, and then delivered to the target location by a non-invasive medical procedure, such as through the use of a delivery catheter through transapical, or transfemoral, or transseptal procedures. The mitral valve replacement device can be released from the delivery system once it reaches the target implant site, and can expand to its normal (expanded) profile either by inflation of a balloon (for a balloon expandable supporting structure) or by elastic energy stored in the device (for a device with a self-expandable supporting structure).
FIGS. 7 and 7A-7E illustrate how the device 00 can be deployed at the mitral annulus of a patient's heart using a transapical delivery system. Referring first to FIG. 7, the delivery system has a catheter which has an outer sheath 30 with a distal tip 37. A center tube 38 extends through the outer sheath 30 and is connected to the distal tip 37, and a marker band 31 1 (see FIG. 7 A) is positioned at the distal end of the outer sheath 30. 32 indicates the left and right of the marker band 31 1 . Two cables 35 and 36 extend through respective tubes 33 and 34, respectively, that run through the interior of the sheath 30. FIG. 7 A illustrates the device 100 in a collapsed configuration being delivered to the mitral annulus inside the sheath 30. In FIG 7B, the sheath 30 is withdrawn (i.e. , moved downwardly) to expose the device so that the self-expanding wire frame 102 will deploy the anterior atrium annulus section 7 and the posterior atrium annulus section 8 in the atrium. In FIG. 7C. the sheath 30 is further withdrawn to release the two cables 35 and 36, and the cables 35 and 36 are detached so that the tails 1 31 and 141 of the wire frame 1 02 can be inserted in the chordae under the native commissure leaflet. As shown in FIGS. 7A- 7D, 51 a is the anterior leaflet, 51 b is the posterior leaflet, 52a is the anterior chordae and 52b is the posterior chordae. Once this occurs, the device 00 is deployed at the native annulus. and in FIG. 7d, the delivery system can be withdrawn . Thus, when the device 100 is deployed, the annulus sections 7 and 8 "seat" at the mitral annulus area to create a "seal" to prevent leakage (blood flow back from the left ventricle to the left atrium) from the area surrounding the device 100, This is best illustrated in FIGS, 6A-6C. In addition, the opening and closing motion of the valve design of the present invention is very similar to the opening and closing motion of a natural mitral valve.
While the description above refers to particular embodiments of the present invention, it will be understood that many modifications may be made without departing from the spirit thereof. The accompanying claims are intended to cover such modifications as would fall within the true scope and spirit of the present invention.

Claims

What is claimed is:
1. A leaflet assembly for use with a prosthetic heart valve, comprising: first and second separate leaflets, each of which is comprised of:
a skirt section having a flange portion and a body portion that has a smaller diameter than the flange portion, the body portion has opposing side edges, and a curved opening defined by a first stitching edge at about the central portion of the body portion; and
a sinus leaflet section having an outflow edge, and a curved second stitching edge, with the sinus leaflet section stitched to the skirt section along the first and second stitching edges
wherein the opposing side edges of the body portion of the first leaflet are stitched to the corresponding side edges of the body portion of the second leaflet.
2. The leaflet assembly of claim 1 , wherein each flange portion has a semi-oval shape,
3. The leaflet assembly of claim 1 , wherein the curved opening is U- shaped.
4. The leaflet assembly of claim 1 , wherein each sinus leaflet section has a generally semi-circular shape.
5. A heart valve assembly, comprising:
a leaflet support structure that comprises a wire frame having an anterior atrium annuius section and a posterior atrium annuius section, with each opposite end of the atrium annuius sections transitioning to a commissure section that curves radially inwardly along the same plane as the atrium annuius sections, and which then transitions via a first bend to a leg which extends vertically at opposite central points of the wire frame, each leg extending vertically and slightly radially outwardly at an angle, and each leg transitioning via a second bend which extends radially outwardly and transitions into a tail that extends vertically upwardly, with a gap defined between each corresponding tail and leg; and
a leaflet assembly having two leaflets that are stitched to the legs and the atrium annuius sections of the wire frame. 1
6. The assembly of claim 5. wherein each atrium annulus section extends horizontally and is shaped like half an oval.
7, The assembly of claim 5, wherein an extension is provided at about the central portion of each atrium annulus section and extends radially outwardly.
8. The assembly of claim 5, the wire frame defines shape selected from the group consisting of: an oval shape, a circular shape, and a D shape.
9. The assembly of claim 5, wherein each tail terminates at a rounded end which curves radially outwardly.
10. The assembly of claim 5. wherein the leaflet assembly has first and second separate leaflets, each of which is comprised of:
a skirt section having a flange portion and a body portion that has a smaller diameter than the flange portion, the body portion has opposing side edges, and a curved opening defined by a first stitching edge at about the central portion of the body portion: and
a sinus leaflet section having an outflow edge, and a curved second stitching edge, with the sinus leaflet section stitched to the skirt section along the first and second stitching edges
wherein the opposing side edges of the body portion of the first leaflet are stitched to the corresponding side edges of the body portion of the second leaflet.
1 1. The assembly of claim 10, wherein each flange portion has a semi-oval shape.
12. The assembly of claim 10. wherein the curved opening is U-shaped.
13. The assembly of claim 10. wherein each sinus leaflet section has a generally semi-circular shape.
PCT/US2015/068020 2015-01-13 2015-12-30 Mitral bileaflet valve Ceased WO2016114928A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP15878296.1A EP3244834B1 (en) 2015-01-13 2015-12-30 Mitral bileaflet valve
CN201580073286.9A CN107205816B (en) 2015-01-13 2015-12-30 mitral bicuspid valve

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/595,433 2015-01-13
US14/595,433 US9579195B2 (en) 2015-01-13 2015-01-13 Mitral bileaflet valve

Publications (1)

Publication Number Publication Date
WO2016114928A1 true WO2016114928A1 (en) 2016-07-21

Family

ID=56366686

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/068020 Ceased WO2016114928A1 (en) 2015-01-13 2015-12-30 Mitral bileaflet valve

Country Status (4)

Country Link
US (2) US9579195B2 (en)
EP (1) EP3244834B1 (en)
CN (1) CN107205816B (en)
WO (1) WO2016114928A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3310301B1 (en) 2015-06-16 2021-05-05 Fondazione Ri.MED Prosthetic heart valve

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
US9427315B2 (en) 2012-04-19 2016-08-30 Caisson Interventional, LLC Valve replacement systems and methods
US9011515B2 (en) 2012-04-19 2015-04-21 Caisson Interventional, LLC Heart valve assembly systems and methods
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
US9421094B2 (en) 2013-10-23 2016-08-23 Caisson Interventional, LLC Methods and systems for heart valve therapy
US9974647B2 (en) 2014-06-12 2018-05-22 Caisson Interventional, LLC Two stage anchor and mitral valve assembly
US9750607B2 (en) 2014-10-23 2017-09-05 Caisson Interventional, LLC Systems and methods for heart valve therapy
US9750605B2 (en) 2014-10-23 2017-09-05 Caisson Interventional, LLC Systems and methods for heart valve therapy
EP3307207A1 (en) 2015-06-12 2018-04-18 St. Jude Medical, Cardiology Division, Inc. Heart valve repair and replacement
US9895222B2 (en) * 2015-08-17 2018-02-20 Venus Medtech (Hangzhou) Inc. Aortic replacement valve
US10456243B2 (en) * 2015-10-09 2019-10-29 Medtronic Vascular, Inc. Heart valves prostheses and methods for percutaneous heart valve replacement
JP7002451B2 (en) 2015-12-15 2022-01-20 ニオバスク ティアラ インコーポレイテッド Transseptal delivery system
CA3010324A1 (en) 2015-12-30 2017-07-06 Caisson Interventional, LLC Systems and methods for heart valve therapy
CN108882981B (en) 2016-01-29 2021-08-10 内奥瓦斯克迪亚拉公司 Prosthetic valve for preventing outflow obstruction
US10383725B2 (en) 2016-08-11 2019-08-20 4C Medical Technologies, Inc. Heart chamber prosthetic valve implant with base, mesh and dome sections with single chamber anchoring for preservation, supplementation and/or replacement of native valve function
GB2557238A (en) * 2016-08-12 2018-06-20 Flugelman Moshe Personalised mitral valve assembly
AU2017361296B2 (en) 2016-11-21 2022-09-29 Neovasc Inc. Methods and systems for rapid retraction of a transcatheter heart valve delivery system
US10653523B2 (en) 2017-01-19 2020-05-19 4C Medical Technologies, Inc. Systems, methods and devices for delivery systems, methods and devices for implanting prosthetic heart valves
US10561495B2 (en) 2017-01-24 2020-02-18 4C Medical Technologies, Inc. Systems, methods and devices for two-step delivery and implantation of prosthetic heart valve
US12029647B2 (en) 2017-03-07 2024-07-09 4C Medical Technologies, Inc. Systems, methods and devices for prosthetic heart valve with single valve leaflet
US12036113B2 (en) 2017-06-14 2024-07-16 4C Medical Technologies, Inc. Delivery of heart chamber prosthetic valve implant
WO2019028264A1 (en) 2017-08-03 2019-02-07 The Regents Of The University Of California Atrial cage for placement, securing and anchoring of atrioventricular valves
US10722353B2 (en) * 2017-08-21 2020-07-28 Edwards Lifesciences Corporation Sealing member for prosthetic heart valve
EP3672530A4 (en) 2017-08-25 2021-04-14 Neovasc Tiara Inc. SEQUENTIAL DEPLOYMENT TRANSCATHETER MITRAL VALVE PROSTHESIS
WO2019164806A1 (en) * 2018-02-22 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inner curvature charge concentration device for tissue laceration
CN108814771B (en) * 2018-03-05 2020-02-21 何铭权 Two-leaf biological valve
US11857441B2 (en) 2018-09-04 2024-01-02 4C Medical Technologies, Inc. Stent loading device
AU2019374743B2 (en) 2018-11-08 2022-03-03 Neovasc Inc. Ventricular deployment of a transcatheter mitral valve prosthesis
US12544226B2 (en) 2019-02-14 2026-02-10 4C Medical Technologies, Inc. Hydrophilic skirt for paravalvular leak mitigation and fit and apposition optimization for prosthetic heart valve implants
CN113747863B (en) 2019-03-08 2024-11-08 内奥瓦斯克迪亚拉公司 Retrievable Prosthesis Delivery System
AU2020256195B2 (en) 2019-04-01 2022-10-13 Neovasc Inc. Controllably deployable prosthetic valve
US11491006B2 (en) 2019-04-10 2022-11-08 Neovasc Tiara Inc. Prosthetic valve with natural blood flow
US11452628B2 (en) 2019-04-15 2022-09-27 4C Medical Technologies, Inc. Loading systems for collapsible prosthetic heart valve devices and methods thereof
CA3282225A1 (en) 2019-05-20 2026-03-02 Neovasc Tiara Inc. Introducer with hemostasis mechanism
JP7520897B2 (en) 2019-06-20 2024-07-23 ニオバスク ティアラ インコーポレイテッド Thin prosthetic mitral valve
US12133797B2 (en) 2020-01-31 2024-11-05 4C Medical Technologies, Inc. Prosthetic heart valve delivery system: paddle attachment feature
US11931253B2 (en) 2020-01-31 2024-03-19 4C Medical Technologies, Inc. Prosthetic heart valve delivery system: ball-slide attachment
US12053375B2 (en) 2020-03-05 2024-08-06 4C Medical Technologies, Inc. Prosthetic mitral valve with improved atrial and/or annular apposition and paravalvular leakage mitigation
US11992403B2 (en) 2020-03-06 2024-05-28 4C Medical Technologies, Inc. Devices, systems and methods for improving recapture of prosthetic heart valve device with stent frame having valve support with inwardly stent cells
US12588998B1 (en) 2022-09-01 2026-03-31 4C Medical Technologies, Inc. Prosthetic heart valve for natural blood flow
US20240366366A1 (en) 2023-03-24 2024-11-07 4C Medical Technologies, Inc. Implant delivery

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3739402A (en) * 1970-10-15 1973-06-19 Cutter Lab Bicuspid fascia lata valve
US4605407A (en) * 1983-01-11 1986-08-12 The University Of Sheffield Heart valve replacements
US20040122513A1 (en) * 2002-10-10 2004-06-24 Navia Jose?Apos; Luis Method and apparatus for replacing a mitral valve with a stentless bioprosthetic valve having chordae
US20050149181A1 (en) * 2004-01-07 2005-07-07 Medtronic, Inc. Bileaflet prosthetic valve and method of manufacture
US20050228496A1 (en) * 2004-04-07 2005-10-13 Medtronic, Inc. Pharmacological delivery implement for use with cardiac repair devices
US20130013058A1 (en) * 2011-07-06 2013-01-10 Waseda University Stentless artificial mitral valve, artificial valve leaflet, template and cutter

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245750B (en) * 1991-05-24 1994-10-14 Sorin Biomedica Emodialisi S R CARDIAC VALVE PROSTHESIS, PARTICULARLY FOR REPLACING THE AORTIC VALVE
US7914569B2 (en) * 2005-05-13 2011-03-29 Medtronics Corevalve Llc Heart valve prosthesis and methods of manufacture and use
JP2012520716A (en) * 2009-03-17 2012-09-10 ミトラシスト メディカル リミテッド Artificial valve having a folding valve and its delivery method
AU2012272855C1 (en) * 2011-06-21 2018-04-05 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US9039757B2 (en) * 2011-10-19 2015-05-26 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
CA2849030C (en) * 2011-10-19 2020-10-27 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US20130310927A1 (en) * 2012-05-18 2013-11-21 James Quintessenza Implantable Valve System
US9872765B2 (en) * 2015-10-12 2018-01-23 Venus Medtech (Hangzhou) Inc Mitral valve assembly

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3739402A (en) * 1970-10-15 1973-06-19 Cutter Lab Bicuspid fascia lata valve
US4605407A (en) * 1983-01-11 1986-08-12 The University Of Sheffield Heart valve replacements
US20040122513A1 (en) * 2002-10-10 2004-06-24 Navia Jose?Apos; Luis Method and apparatus for replacing a mitral valve with a stentless bioprosthetic valve having chordae
US20050149181A1 (en) * 2004-01-07 2005-07-07 Medtronic, Inc. Bileaflet prosthetic valve and method of manufacture
US20050228496A1 (en) * 2004-04-07 2005-10-13 Medtronic, Inc. Pharmacological delivery implement for use with cardiac repair devices
US20130013058A1 (en) * 2011-07-06 2013-01-10 Waseda University Stentless artificial mitral valve, artificial valve leaflet, template and cutter

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3310301B1 (en) 2015-06-16 2021-05-05 Fondazione Ri.MED Prosthetic heart valve
EP3310301B2 (en) † 2015-06-16 2024-02-21 Fondazione Ri.MED Prosthetic heart valve

Also Published As

Publication number Publication date
EP3244834A1 (en) 2017-11-22
US9895220B2 (en) 2018-02-20
CN107205816B (en) 2019-05-21
EP3244834B1 (en) 2020-11-04
US20160199180A1 (en) 2016-07-14
US20170143486A1 (en) 2017-05-25
US9579195B2 (en) 2017-02-28
EP3244834A4 (en) 2018-08-01
CN107205816A (en) 2017-09-26

Similar Documents

Publication Publication Date Title
US9895220B2 (en) Mitral bileaflet valve
CN112336498B (en) Mitral valve components
US10543082B2 (en) Heart valve assembly
JP7087092B2 (en) Expandable frame and perivalvular leak mitigation system for implantable prosthetic valve devices
JP2023184533A (en) Artificial valve leaflet device
CN107787209B (en) percutaneous mitral valve replacement device
JP2019500994A (en) Implants and methods for improving atrioventricular valve bonding
CN103068341A (en) Mitral prosthesis
US20240197469A1 (en) Devices and systems for docking a heart valve
US20250099236A1 (en) Replacement Heart Valve
HK40045359A (en) Mitral valve assembly
HK40051876A (en) Mitral valve assembly
CA2984246C (en) Heart valve assembly
HK1249393B (en) Heart valve assembly
HK1249395B (en) Mitral valve assembly

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15878296

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015878296

Country of ref document: EP